Recent Quotes

Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-04
REV		(EXPECTED)2021-08-04

Q1 2021		Est.		Actual		Surprise
EPS		-0.480		-0.600		-0.1200
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
LYRA	Lyra Therapeutics	9.19	0.19	2.11%		119.5M

Lyra Therapeutics Frequently Asked Questions

How do I buy Lyra Therapeutics (LYRA) stock?

You can purchase shares of Lyra Therapeutics (NASDAQ: LYRA) through any online brokerage.

View our list of the best stock brokerages.

Who are Lyra Therapeutics's (LYRA) competitors?

Other companies in Lyra Therapeutics’s space includes: Graybug Vision (NASDAQ:GRAY), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX), Ocuphire Pharma (NASDAQ:OCUP) and Lipocine (NASDAQ:LPCN).

What is the target price for Lyra Therapeutics (LYRA) stock?

The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by B of A Securities on May 26, 2020. The analyst firm set a price target for 21.00 expecting LYRA to rise to within 12 months (a possible 128.51% upside). 0 analyst firms have reported ratings in the last year.

Current Stock Price for Lyra Therapeutics (LYRA)?

The stock price for Lyra Therapeutics (NASDAQ: LYRA) is $9.19 last updated Fri Jun 11 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Does Lyra Therapeutics (LYRA) pay a dividend?

There are no upcoming dividends for Lyra Therapeutics.

When is Lyra Therapeutics (NASDAQ:LYRA) reporting earnings?

Lyra Therapeutics’s Q2 earnings are confirmed for after-market on August 4, 2021.

Is Lyra Therapeutics (LYRA) going to split?

There is no upcoming split for Lyra Therapeutics.

What sector and industry does Lyra Therapeutics (LYRA) operate in?

Lyra Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.